Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) PT at $36.75

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) have earned a consensus rating of “Hold” from the six ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $36.75.

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Ascendiant Capital Markets reaffirmed a “buy” rating and set a $48.00 price objective (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, BTIG Research reaffirmed a “buy” rating and set a $25.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of NRXP. Ethos Financial Group LLC acquired a new stake in shares of NRx Pharmaceuticals in the 3rd quarter worth $39,000. Sjbenen Advisory LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $41,000. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the period. Two Sigma Investments LP raised its holdings in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after purchasing an additional 37,598 shares during the period. 4.27% of the stock is owned by institutional investors and hedge funds.

NRx Pharmaceuticals Trading Up 2.4%

Shares of NRXP stock opened at $2.15 on Tuesday. The company has a market cap of $63.64 million, a P/E ratio of -0.91 and a beta of 1.92. The firm has a fifty day moving average price of $2.31 and a 200 day moving average price of $2.64. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $6.83 million. On average, equities analysts forecast that NRx Pharmaceuticals will post -1.75 EPS for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.